Paper29889239
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Chu CS and 20 others. Clin Infect Dis, 2018. Cited by 59 papers, by iCite.
Cite this record
ConductScience Library. Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. Papers, record 29889239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29889239
- Disease
- Plasmodium vivax malaria28 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antimalarials | Major topic |
| Artesunate | Major topic |
| Chloroquine | Major topic |
| Malaria, Vivax | Major topic |
| Primaquine | Major topic |
| Adolescent | |
| Adult | |
| Child | |
| Child, Preschool | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Infant | |
| Male | |
| Middle Aged | |
| Myanmar | |
| Parasitemia | |
| Plasmodium vivax | |
| Recurrence | |
| Thailand | |
| Treatment Outcome | |
| Young Adult |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Wellcome Trust | United Kingdom | PubMed | ||
| 089179/Z/09/Z | Wellcome Trust | United Kingdom | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01074905 | Study on the Treatment of Vivax Malaria | Derived from the trial | Yes |
Source ClinicalTrials.gov
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23472056 | Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999-2011: an observational study. | PLoS Med | 2013 | https://conductscience.org/library/papers/23472056 | PubMed |
| 2 | 11716124 | Factors contributing to anemia after uncomplicated falciparum malaria. | Am J Trop Med Hyg | 2001 | https://conductscience.org/library/papers/11716124 | PubMed |
| 3 | 8133114 | Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. | J Infect Dis | 1994 | https://conductscience.org/library/papers/8133114 | PubMed |
| 4 | 26888075 | Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. | Malar J | 2016 | https://conductscience.org/library/papers/26888075 | PubMed |
| 6 | 26437860 | Malaria ecology along the Thailand-Myanmar border. | Malar J | 2015 | https://conductscience.org/library/papers/26437860 | PubMed |
| 7 | 10674098 | Treatment of vivax malaria on the western border of Thailand. | Trans R Soc Trop Med Hyg | 1999 | https://conductscience.org/library/papers/10674098 | PubMed |
| 8 | 21989376 | Determinants of relapse periodicity in Plasmodium vivax malaria. | Malar J | 2011 | https://conductscience.org/library/papers/21989376 | PubMed |
| 9 | 10817728 | Therapeutic responses to different antimalarial drugs in vivax malaria. | Antimicrob Agents Chemother | 2000 | https://conductscience.org/library/papers/10817728 | PubMed |
| 10 | 12499187 | Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic. | Antimicrob Agents Chemother | 2003 | https://conductscience.org/library/papers/12499187 | PubMed |
| 11 | 18563961 | Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. | PLoS Med | 2008 | https://conductscience.org/library/papers/18563961 | PubMed |
| 12 | 18563962 | Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. | PLoS Med | 2008 | https://conductscience.org/library/papers/18563962 | PubMed |
| 13 | 22002979 | Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. | Clin Infect Dis | 2011 | https://conductscience.org/library/papers/22002979 | PubMed |
| 14 | 23782898 | The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. | Malar J | 2013 | https://conductscience.org/library/papers/23782898 | PubMed |
| 15 | 22966124 | Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. | J Infect Dis | 2012 | https://conductscience.org/library/papers/22966124 | PubMed |
| 16 | 26654101 | Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. | BMC Med | 2015 | https://conductscience.org/library/papers/26654101 | PubMed |
| 17 | 23254437 | Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/23254437 | PubMed |
| 18 | 28170391 | Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens. | PLoS Med | 2017 | https://conductscience.org/library/papers/28170391 | PubMed |
| 19 | 25073652 | Modelling recurrent events: comparison of statistical models with continuous and discontinuous risk intervals on recurrent malaria episodes data. | Malar J | 2014 | https://conductscience.org/library/papers/25073652 | PubMed |
| 20 | 9230792 | Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. | Am J Trop Med Hyg | 1997 | https://conductscience.org/library/papers/9230792 | PubMed |
| 21 | 18046504 | Glucose-6-phosphate dehydrogenase mutations in Mon and Burmese of southern Myanmar. | J Hum Genet | 2008 | https://conductscience.org/library/papers/18046504 | PubMed |
Cited by54
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 59 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41960341 | Frequent and genetically diverse Plasmodium vivax relapses contribute to malaria transmission in Cambodia. | Res Sq | 2026 | https://conductscience.org/library/papers/41960341 | PubMed |
| 41541400 | Plasmodium vivax Malaria Relapse Risk Depends on Transmission Intensity: Evidence From a Longitudinal Study in Northwest Thailand. | Open Forum Infect Dis | 2026 | https://conductscience.org/library/papers/41541400 | PubMed |
| 41239453 | Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis. | Malar J | 2025 | https://conductscience.org/library/papers/41239453 | PubMed |
| 40518540 | Efficacy of chloroquine with primaquine for uncomplicated Plasmodium vivax malaria without G6PD testing in Northwest Ethiopia: a one-arm in vivo prospective therapeutic efficacy study. | Malar J | 2025 | https://conductscience.org/library/papers/40518540 | PubMed |
| 40420173 | Does mass chloroquine treatment have any role in the elimination of Plasmodium vivax ? | Malar J | 2025 | https://conductscience.org/library/papers/40420173 | PubMed |
| 40247375 | [Effect of low-dose primaquine treatment on Plasmodium vivax recurrence and transmission-blocking activity in southwest Ethiopia: a longitudinal cohort study. | Malar J | 2025 | https://conductscience.org/library/papers/40247375 | PubMed |
| 40152264 | Efficacy of Primaquine for the Radical Cure of Plasmodium vivax Malaria in Northeast Myanmar and the Impact of Cytochrome P450 2D6 Genotypes. | Clin Infect Dis | 2025 | https://conductscience.org/library/papers/40152264 | PubMed |
| 40112852 | 14 days of high-dose versus low-dose primaquine treatment in patients with Plasmodium vivax infection in Cambodia: a randomised, single-centre, open-label efficacy study. | Lancet Infect Dis | 2025 | https://conductscience.org/library/papers/40112852 | PubMed |
| 39820011 | A mixed methods study investigating factors affecting adherence to Plasmodium vivax malaria primaquine radical cure regimens among migrants along the Myanmar-Thailand border. | PLOS Glob Public Health | 2025 | https://conductscience.org/library/papers/39820011 | PubMed |
| 39332427 | Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis. | Lancet Child Adolesc Health | 2024 | https://conductscience.org/library/papers/39332427 | PubMed |
| 39331646 | Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis. | PLoS Med | 2024 | https://conductscience.org/library/papers/39331646 | PubMed |
| 39117628 | Lineage-informative microhaplotypes for recurrence classification and spatio-temporal surveillance of Plasmodium vivax malaria parasites. | Nat Commun | 2024 | https://conductscience.org/library/papers/39117628 | PubMed |
| 38041857 | Effectiveness of an Unsupervised Primaquine Regimen for Preventing Plasmodium vivax Malaria Relapses in Northeast Myanmar: A Single-Arm Nonrandomized Observational Study. | J Infect Dis | 2024 | https://conductscience.org/library/papers/38041857 | PubMed |
| 37817240 | Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. | Malar J | 2023 | https://conductscience.org/library/papers/37817240 | PubMed |
| 37748497 | Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. | Lancet Infect Dis | 2024 | https://conductscience.org/library/papers/37748497 | PubMed |
| 37748496 | Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. | Lancet Infect Dis | 2024 | https://conductscience.org/library/papers/37748496 | PubMed |
| 36534705 | Population heterogeneity in Plasmodium vivax relapse risk. | PLoS Negl Trop Dis | 2022 | https://conductscience.org/library/papers/36534705 | PubMed |
| 36472067 | The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis. | Elife | 2022 | https://conductscience.org/library/papers/36472067 | PubMed |
| 36296297 | Molecular Profiles of Multiple Antimalarial Drug Resistance Markers in Plasmodium falciparum and Plasmodium vivax in the Mandalay Region, Myanmar. | Microorganisms | 2022 | https://conductscience.org/library/papers/36296297 | PubMed |
| 35739554 | Prolonged fever and exaggerated hypercoagulopathy in malaria vivax relapse and COVID-19 co-infection: a case report. | Malar J | 2022 | https://conductscience.org/library/papers/35739554 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CYP2D6 | 1565 | PubTator's text mining | https://conductscience.org/library/genes/1565 | NCBI Gene |
| G6PD | 2539 | PubTator's text mining | https://conductscience.org/library/genes/2539 | NCBI Gene |
| HBG2 | 3048 | PubTator's text mining | https://conductscience.org/library/genes/3048 | NCBI Gene |
Drugs3
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| ARTESUNATE | CHEMBL361497 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL361497 | ChEMBL |
| PRIMAQUINE | CHEMBL506 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL506 | ChEMBL |
| CHLOROQUINE | CHEMBL76 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL76 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29889239
GET https://conductscience.org/api/papers/v1/29889239/authors?page=2